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Dapagliflozin: A Newly Approved SGLT2 Inhibitor
for the Treatment of Type 2 Diabetes Mellitus
Ann Marie Ruhe, fifth-year pharmacy student from Cincinnati, Ohio; Rachel Muhlenkamp, fourth-year pharmacy student
from Findlay, Ohio; Austin Brown, fourth-year pharmacy student from Forest, Va.; Emily Blum, fifth-year pharmacy student
from Buffalo, N.Y.; Sandra L. Hrometz, BSPh '94, Ph.D., R.Ph., CGP, professor of pharmacology

This knowledge-based activity is targeted for all pharmacists
and is acceptable for .75 hour (.075 CEU) of continuing
education credit. This course requires completion
of the program evaluation and at least a 70 percent grade
on the program assessment questions.

ACPE Universal Activity Number (UAN): 0048-0000-14-174-HO 1-P
Objectives
After completion of this program, the reader should be able
to:
1. Identify the mechanism of action and pharmacological
implications of therapy with dapagliflozin.
2. Explain dapagliflozin's place in therapy in the treatment of diabetes.
3. Describe possible advantages of combination therapy
with current diabetes medications.
4. Identify the appropriate monitoring requirements for
dapagliflozin treatment.
5. Discuss the various side effects associated with dapagliflozin use.

MOA/Pharmacology/Kinetics
Reabsorption of glucose in the kidney is reliant on the
mechanism of the SGLT2 protein, a low-affinity, highcapacity 1:1 sodium/glucose transporter.3 Its characterization as a low-affinity transporter indicates that a molecule of
glucose attaches to the protein with less force and at an abbreviated time interval as compared to a high-affinity counterpart, sodium-glucose cotransporter 1 (SGLTl). Nearly the
entire portion of the 144 grams of glucose filtered by the
glomerulus on a 24 hour basis is reabsorbed in the renal tubules.4 The SGLT2 is highly expressed in the Sl segment of
the proximal convoluted tubule and serves as the primary
site for mammalian glucose reabsorption.3 A second sodium/
glucose cotransporter, SGLTl, is present in both the kidney
and the intestine. The SGL Tl is characterized as high-affinity
and possesses the additional capacity for galactose transport
that is absent in SGLT2.3 The SGLTl is located in the S3 segment of the proximal tubule to reabsorb any remaining glucose that escaped transport by SGL T2 from the lumen into
the bloodstream (Figure 1).

Abstract
Type 2 diabetes mellitus (T2DM) is a chronic disease in
which a hyperglycemic state is induced by insulin resistance.
While there are numerous treatment options available to
manage T2DM, many patients require changes in therapy
throughout treatment, as well as multiple medications. The
sodium/glucose cotransporter 2 (SGLT2) inhibitors, canagliflozin and dapagliflozin, offer a therapeutic alternative in
T2DM management through the utilization of a unique
mechanism of action to provide intensified glycemic control.
This article will evaluate the safety and efficacy of dapagliflozin in the management ofT2DM.

Inability to reach glycemic targets in addition to prevalent
side effects of existing therapies has prompted researchers to
investigate therapeutic alternatives. Selective inhibition of
SGLT2 is a viable alternative in the treatment of T2DM.3 During hyperglycemia, SGLT2 is upregulated in an attempt to
meet the demand of additional glucose reabsorption. Selective inhibition of these transporters in the hyperglycemic
state of diabetic patients results in elevated urinary glucose
levels and decreased blood glucose levels. Canagliflozin and
dapagliflozin are both approved for use as adjuncts to diet
and exercise in adult diabetic patients who are not adequately controlled on metformin or a sulfonylurea.2 Because
of the novelty of this drug class and limited clinical experience with its members, trials directly comparing canagliflozin and dapagliflozin therapy have yet to be conducted.

Introduction
The recent introduction of the sodium/glucose cotransporter
2 (SGL T2) inhibitor drug class presents a novel treatment
option in the type 2 diabetes mellitus (T2DM) therapeutic
arsenal. Janssen Pharmaceuticals, Inc. manufactures the inaugural member of this class, canagliflozin (Invokana®),
which gained U.S. Food and Drug Administration (FDA) approval in 2013.1 The introduction of dapagliflozin (Farxiga®)
by Bristol-Myers Squibb, which was granted approval in
early 2014, offers a second, "me too," alternative to this novel
class.2 Both canagliflozin and dapagliflozin are oral agents
indicated to improve glycemic control in conjunction with
dietary and exercise modifications in patients not adequately
responding to current therapy.1.2

Dapagliflozin reaches maximum plasma concentration within
two hours of fasting administration, and the oral bioavailability of a standard 10 mg dose is 78 percent.2 It can be taken
without regard to meals. Dapagliflozin is 91 percent protein
bound, and UGT1A1, an enzyme in the glucuronidation pathway, is responsible for the majority of its metabolism to an
inactive metabolite, dapagliflozin 3-0-glucuronide. It is primarily eliminated through the kidneys with a mean plasma
terminal half-life of 12.9 hours subsequent to a single 10 mg
oral dose. In vitro, dapagliflozin did not significantly impact
the pharmacokinetics of coadministered drugs, nor did the
coadministered drugs significantly impact dapagliflozin.
Therefore, no dosing adjustments need to be made during
concurrent therapy with other oral medications based on
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Figure 1. Diagram of a Kidney Nephron
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pharmacokinetics. The pharmacokinetic parameters of canagliflozin are similar, with 65 percent oral bioavailability
and 99 percent protein binding; primarily to albumin.1 Canagliflozin undergoes 0-glucuronidation as the major metabolic elimination pathway to two inactive metabolites.
Indication/Usage
Type 2 diabetes mellitus is characterized by chronic hyperglycemia resulting from the development of insulin resistance, impaired insulin secretion and increased hepatic
glucose production.s A strength of the SGLT2 inhibitor class
is its ability to work independently of insulin. By removing
insulin resistance as a confounding interference in treatment,
significant reductions in blood glucose levels can occur regardless of a patient's degree of insulin resistance. Therefore,
SGLT2 inhibitors are a viable option for type 2 diabetics with
substantial insulin resistance. Dapagliflozin has been studied
and approved for use as both monotherapy and combination
therapy.2
Dosing, Frequency and Side Effects
The recommended starting dose of dapagliflozin is 5 mg once
daily, which can be increased to 10 mg once daily if well tolerated and the patient requires intensified glycemic controJ.2
It should be taken in the morning without regard to meals.
Patients with pre-existing volume abnormalities should be
regulated prior to use. Through clinical trial evaluation, daJuly 2014 Volume 5, Issue 3

pagliflozin therapy has been most directly associated with
adverse events including female genital mycotic infections,
nasopharyngitis and urinary tract infections.6 A reduction in
body weight was observed when dapaglifozin was used in
combination with other OM medications. It is contraindicated in those with known hypersensitivity to dapagliflozin,
severe renal impairment, end stage renal disease (ESRD) and
patients on dialysis.2

UT/sand Genital Infections
According to a retrospective cohort study performed by Iglay
and colleagues, patients with T2DM were more likely to have
a urinary tract infection (UTI) compared to the general population.7 Multiple studies evaluating the safety and efficacy of
dapagliflozin have also reported a higher incidence of UTis
and genital infections in those patients receiving dapagliflozin than in patients receiving a placebo. A meta-analysis
by Johnsson and colleagues pooled twelve randomized placebo-controlled trials of patients receiving dapagliflozin or
placebo for either 12 or 24 weeks.B,9 While various other dosing strengths were utilized in the trials, they only reviewed
the incidence of UTis and genital infections for dapagliflozin
2.5, 5 and 10 mg groups, as these were the doses pursued in
further drug development. Within these groups, a slightly
higher incidence of UTI occurred in the 5 mg and 10 mg
groups compared to the 2.5 mg and placebo groups
(2.5 mg-3.6%, p=0.8373; 5 mg-5.7%, p=0.0201; 10 mg-
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4.3%, p=0.4823; placebo-3.7%), of which only 5 mg
reached statistical significance assuming a traditional p value
of 0.05.s There was also a statistically significant increased
number of genital infections (including vulvovaginal mycotic
infection, vaginal infection, vulvovaginal candidiasis and
genital fungal infection), vulvovaginal pruritus, genital
pruritus and balanitis in all of the dapagliflozin groups in
comparison to the placebo groups (5 mg-5.7%, p<0.0001;
10 mg-4.8 percent, p<0.0001; 2.5 mg-4.1 percent,
p<0.0001; placebo-2.1%).9 A higher incidence was also reported in women in comparison to men and in patients with
a history of recurrent genital infections. The researchers did
not find the rate of genital infections to be directly related to
dose, in that they did not increase consistently with each
dose increment. Collectively, the genital infections were all
classified as mild to moderate, except for one severe case. All
were efficiently treated using standard therapy.s.9
Special Populations

Pregnancy
Dapagliflozin is a pregnancy category C drug, indicating that
animal studies have shown risks to the fetus but sufficient
human studies have not been performed. In this case, the
development of the kidneys may be compromised during the
second and third trimester. The risks to the fetus, as well as
the benefit of treatment for the mother, should be evaluated
before administration of dapagliflozin in pregnancy.z

Renal Impairment
Kasichayanula and colleagues evaluated the effects that renal
impairment would have on the glycemic effects of dapagliflozin.10 Type 2 diabetics with varying levels of renal impairment based on creatinine clearance and supported by
iohexol administration were evaluated. Renal function was
defined as: no impairment, or normal renal function (CLcR >
80 ml/min), mild impairment (CLCR51-80 mljmin), moderate impairment (CLCR 30-50 ml/min), and severe impairment
(CLrn <30 ml/min). They found that there was no significant
difference in urinary glucose levels after administration of
dapagliflozin in the non-renal impairment and mild renal
impairment groups. Unexpectedly, those in the moderate and
severe renal impairment groups had lower urinary glucose
levels in comparison to the groups with better renal function,
despite increased half-life and drug accumulation. Even
though the half-life of dapagliflozin was increased in those
with moderate and severe renal impairment, the researchers
found this decrease in urinary glucose elimination to be due
to the decreased glomerular filtration rate (GFR). Because
the GFR was significantly reduced in the moderate and severe impairment patients, there was a decrease in renal fluid
movement, therefore less glucose was able to reach the
SGLT2 receptors in the proximal tubule of the kidney despite
the increased half-life of dapagliflozin. Renal function testing
was not, however, available after dapagliflozin administration in this study, therefore it is unclear if some of the
impairment was caused by the drug or if it was completely
independent of dapagliflozin.
Dapagliflozin should be discontinued in those with a glomerular filtration rate of less than 60 ml/min or those with end-
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stage kidney disease. 2 Dapagliflozin is not recommended in
patients undergoing hemodialysis, as this has not been studied.

Hepatic Impairment
There are currently no recommendations in regard to impaired liver function and dapagliflozin administration because safety has not been evaluated.z
Efficacy of Monotherapy
Dapagliflozin is approved for use alone or in conjunction
with other T2DM medications in order to appropriately stabilize and lower the patient's risk for hyperglycemia and decrease hemoglobin Ale (HbAtc) levels.2 Two monotherapy
studies to evaluate its efficacy are discussed below.

In a randomized, double-blinded, placebo-controlled phase
III trial, Ferrannini and colleagues studied the effects of
dapagliflozin in T2DM patients who had poorly controlled
hyperglycemia when using diet and exercise as their only
intervention.1 1Two weeks before the study began subjects
were given a placebo in addition to counseling on proper diet
and exercise. Subjects were then divided into placebo and
dapagliflozin groups. The dapagliflozin groups were further
subdivided into 2.5, 5, or 10 mg groups and morning or evening administration. Results presented below are for the
5 mg and 10 mg daily doses only, as there were no significant
changes in the 2.5 mg daily group. After 24 weeks, a statistically significant decrease in HbA1c from baseline (primary
end point) was seen in the 5 mg (-0.58%, p=0.0005) and
10 mg (-0.89%, p<0.0001) dapagliflozin groups compared to
placebo (-0.23%, assuming a p<0.05, although not explicitly
stated). Dapagliflozin also significantly decreased fasting
plasma glucose from baseline (secondary end point) in comparison to the placebo group. Utilizing a 95 percent confidence interval, the placebo group's fasting plasma glucose
decreased by 4.lmg/dL from baseline (-11.8-3.5), the 5 mg
group's decreased by 24.1 mg/dL (-32.5-15.6) from baseline,
and the 10 mg group's decreased by 28.8 mg/dL (-36.8-20.9)
from baseline. A slight increase in weight loss and decrease
in blood pressure was also noted for the dapagliflozin group,
although it was not statistically significant. Administration in
the morning in comparison to evening yielded similar results. Finally, dapagliflozin monotherapy did not significantly
alter electrolyte, serum albumin, serum creatinine or blood
urea nitrogen levels.
A second randomized, double-blinded, placebo-controlled,
parallel-group, phase Ill study was conducted by Ji and colleagues in order to evaluate the efficacy of dapagliflozin
monotherapy in the Asian population.12 The selected patients
included T2DM patients who were drug naive, using inclusion criteria similar to the study conducted by Ferrannini et
al.11 HbA1cwas measured in the placebo, 5 mg and 10 mg
groups over a 24-week period. Compared to placebo the dapagliflozin groups had a significant reduction in HbA1cfrom
baseline. The 5 mg dapagliflozin group had a 1.04 percent
(p < 0.0001) reduction from baseline, the 10 mg dapagliflozin
group had a 1.11 percent (p < 0.0001) reduction from baseline, and the placebo group had a 0.29 percent reduction
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Table 1. Summary of Dapagliflozin Clinical Trials
Reference
Bailey, et al.

Stroj ek, et al.

Rosenstock, et al.
Pioglitazone
dose was either
30 or45 mg
daily
(24weeks)
Rosenstock, et al.
Pioglitazone
dose was either
30 or45 mg
daily
(48 weeks)

Treatment groups

Number of
subjects*

Decrease in HbA1c from
baseline (p value)**

Change in weight from
baseline (p value)**

Metformin + placebo

134

0.3%

0.9 kg loss

Metformin + 2.5 mg Dapagliflozin

135

0.67% (p

Metformin + 5 mg Dapagliflozin

133

0.7% (p < 0.0001)

3 kg loss (p < 0.0001)

Metformin + 10 mg Dapagliflozin

132

0.84% (p < 0.0001)

2.9 kg loss (p < 0.0001)

4 mg glimepiride + placebo

143

0.13%

0.72 kg loss

4 mg glimepiride +
2.5 mg dapagliflozin

154

0.58% (p < 0.0001)

1.18 kg loss (p
0.1410)

=

4 mg glimepiride +
5 mg dapagliflozin

142

0.63% (p < 0.0001)

1.56 kg loss (p
0.0091)

=

4 mg glimepiride +
10 mg dapagliflozin

150

0.82% (p < 0.0001)

2.26 kg loss (p <0.0001)

Pioglitazone + placebo

139

0.42%

1.64 kg gain

Pioglitazone + 5 mg Dapagliflozin

141

0.82% (p

= 0.0007)

0.09 kg gain (p <
0.0001)

Pioglitazone +
10 mg Dapagliflozin

140

0. 97% (p < 0.0001)

0.14 kg loss (p <
0.0001)

Pioglitazone + placebo

139

0.54%

2.99 kggain

Pioglitazone + 5 mg Dapagliflozin

141

0.95%

1.35 kg gain

Pioglitazone +
10 mg Dapagliflozin

140

1. 21%

0.69 kg gain

= 0.0002)

2.2 kg loss (p < 0.0001)

*Number of subjects that completed the trials and were included in statistical analyses
** p-values are listed only if reported by the authors
from baseline. In general, monotherapy with dapagliflozin
appears to have a statistically significant impact on HbA1c.
Coadministration Therapy
Dapagliflozin has also been studied in combination with metformin, glimepiride and pioglitazone. Each of the following
studies were randomized, double-blinded, placebocontrolled trials in subjects with inadequately controlled
T2DM. The primary outcome was change in HbAic from baseline after 24 weeks of treatment. In all three studies, the combination therapy resulted in a significant decrease in HbA1c from
baseline and favorable effects on patient baseline weight.6,13,14
A summary of the results is presented in Table 1.
In a study conducted by Bailey and colleagues, all participants remained on their original metformin therapy throughout the trial.13 The results showed a statistically significant
decrease in HbA1c and body weight from baseline at week 24
compared to placebo plus metformin.

July 2014 Volume 5, Issue 3

The next two studies investigated the combination of dapagliflozin with glimepiride or pioglitazone. Combination with a
sulfonylurea (glimepiride) and thiazolidinedione (pioglitazone)
were of particular interest because they also reported on the
influence of dapagliflozin to combat the weight gain associated with sulfonylureas and thiazolidinediones as well as the
edema associated with thiazolidinediones.6.14
The efficacy of combination dapagliflozin and sulfonylurea
therapy was assessed in a clinical trial conducted by Strojek
and colleagues. 6 Regardless of the original sulfonylurea used,
all subjects were switched to glimepiride 4 mg/day with an
eight-week lead-in period. The results showed a statistically
significant decrease in HbA1c and body weight from baseline
at week 24 compared to placebo, except for body weight with
dapagliflozin 2.5 mg.
Pioglitazone is known to result in weight gain and peripheral
edema, while dapagliflozin results in diuresis and is associated with weight loss. Naturally, a combination therapy
might then be of considerable benefit. Rosenstock and col-
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leagues studied the efficacy and side effect incidence in 420
subjects receiving combination therapy with pioglitazone.14
During a 10-week dose-optimization period preceding the
trial, all participants were put on pioglitazone 30 mg/day
and increased to 45 mg/day if tolerated. At the end of the
twenty-four week study, patients in the dapagliflozin group
had significant mean reductions in HbA1c. In the 24 week
extension of this trial, those receiving dapagliflozin had additional HbA1c reductions, but no statistical analysis was performed.

statistically significant for all observed doses, both as monotherapy or in combination with other agents. No significant
impact on therapeutic efficacy was observed upon variation
of dosing or duration, and improvements in overall glycemic
control remained consistent across agents. Dapagliflozin and
canagliflozin therapies demonstrated a statistically significant occurrence of genital tract infections, and a higher
prevalence of UTis was noted with dapagliflozin therapy in
comparison with canagliflozin. Additionally, one study established an increased risk of vulvovaginal candidiasis in canagliflozin patients, which did not seem to impact those taking dapagliflozin to the same degree. Mycotic infections were
generally more prevalent in patients with a previous history.
Regardless of doses and frequency of therapy used
(canagliflozin: 50 mg QD - 300 mg BID, dapagliflozin: 1 mg
QD -50 mg QD, empagliflozin: 5 mg QD - 25 mg QD, ipragliflozin: 12.5 mg QD - 300 mg QD), there were no significant
differences in dropout rates between treatment and placebo
groups. 15

Side effects of weight gain and peripheral edema were measured at 24 and 48 weeks.14 At week 24, the placebo plus
pioglitazone group had a 1.64 kg weight gain, while the combination therapy groups had a 0.09 kg gain with 5 mg and a
0.14 kg loss with 10 mg dapagliflozin. Statistical significance
was found between the placebo and the dapagliflozin groups
at week 24. At week 48, the placebo plus pioglitazone group
had a 2.99 kg weight gain, while the combination therapy
groups had weight gains of 1.35 kg with 5 mg and 0.69 kg
with 10 mg. However, statistical analysis was not performed.14 The incidence of peripheral edema was evaluated
at week 48. Overall, 6.5 percent of those receiving pioglitazone plus placebo experienced peripheral edema, while only
4.3 percent experienced peripheral edema with 5 mg dapagliflozin plus pioglitazone and 2.1 percent experienced it with
10 mg dapagliflozin plus pioglitazone.

Cost
Although specific pricing information has not yet been released by AstraZeneca and Bristol-Myers Squibb, patients
meeting certain age and insurance criteria are eligible to participate in the Farxiga SavingsRx program to alleviate the
potential financial burdens of dapagliflozin therapy.16

Considering the decreased peripheral edema and lessened
weight gain observed in the experimental groups, dapagliflozin appears to have attenuated the adverse effects of
pioglitazone, although statistical analysis was not performed
for the 48-week end points. 14 Therefore, dapagliflozin may
be a reasonable option for combination therapy with pioglitazone.
Although dapagliflozin combination therapy was associated
with better HbA1c outcomes than metformin, glimepiride and
pioglitazone monotherapies, adverse events may limit its
use. As would be expected with increases in urine glucose
levels, genital infections were higher in dapagliflozin groups
than in the placebo groups.6,13,14 On the other hand, UTis
were observed with similar prevalence across all groups in
the combination therapy trials. Hypoglycemia was also monitored closely. The Bailey et al. and Rosenstock et al. trials
reported similar proportions of hypoglycemia between the
placebo and the dapagliflozin groups.13,14 However, in the
Strojek et al. trial, the dapagliflozin groups had more frequent hypoglycemia (6.9-7.9%) than the placebo (4.8%).6

Monitoring
The traditional monitoring of T2DM also applies to dapagliflozin including regular HbA1c and renal function tests.
Additionally, annual check-ups to monitor for diabetic complications should be performed by specialists such as a cardiologists, podiatrists and ophthalmologists. As with other anti
-diabetic medications, hypoglycemia is a possibility and
should be monitored. Patients specifically taking SGLT2 inhibitors are also at risk for hypovolemia due to increased
blood glucose leading to increased urine excretion. Other
complications of hypovolemia include orthostatic hypotension or hypotension, so the importance of staying adequately
hydrated while taking dapagliflozin should be stressed. For
geriatric patients, dosage adjustments do not need to be
made unless that patient has moderate to severe impaired
renal function (CrCl :5 60 ml/min) or end-stage kidney disease.2 A phase 1 clinical trial is currently recruiting patients
age 10 to 17 years, diagnosed with T2DM, to evaluate the
pharmacokinetics and pharmacodynamics of dapagliflozin in
that specific patient population.17

Comparison ofDapagliflozin and Canagliflozin
A meta-analysis of randomized, double-blinded, controlled
trials was conducted by Berhan and Barker in 2013, to evaluate the safety and efficacy of a number of studied SGLT2 inhibitors accounting for variations in the dosing regimen as
monotherapy and combination therapy.is This meta-analysis
included 17 total studies of dapagliflozin, canagliflozin, ipragliflozin and empagliflozin conducted in human patients.
Reductions from baseline in HbA1c (-0.78%, 95% CI, -0.87 to 0.69), fasting plasma glucose (-0.70%, 95% Cl, -0.79 to -0.61)
and body weight (-0.59%, 95% CI, -0.65 to -0.52) were

Conclusion
Dapagliflozin (Farxiga®), an oral "me too" alternative to canagliflozin, is a recently approved SGLT2 inhibitor for the
treatment of T2DM. Due to the insulin independent nature of
the mechanism, both dapagliflozin and canagliflozin have the
potential to be a therapeutic niche for patients with a high
degree of insulin resistance. As a relatively new class of diabetic medications, there remains a lack of head-to-head comparison data in regard to significant discrepancies in clinical
efficacy. Adequate hydration and frequent monitoring of
fluid status and renal function are important considerations
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in all patients. Although no hepatic or renal dosing adjustments are recommended, dapagliflozin should be discontinued in end stage renal disease or if GFR falls below 60 ml/
min. Contraindications to therapy include known hypersensitivity, severe renal impairment and hemodialysis. The most
common adverse events include genital mycotic infections
and UTis, with the highest incidence in women and those
with a history of prior genital infections. Clinical trials indicate statistically· significant reductions in fasting plasma glucose and HbA1c compared to placebo when dapagliflozin is
used as monotherapy. Studies also have shown a significantly
greater reduction in HbA1c in combination therapy containing dapagliflozin as compared to monotherapy with an alternative antidiabetic agent. Although the high incidence of adverse events and cost may ultimately limit its clinical utility,
this novel therapy presents a potential therapeutic consideration for patients requiring greater glycemic control.

Endocrine
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Assessment Questions

1.

In which of the following patient populations is dapagliflozin most appropriately indicated?
A. TlDM patients
B. T2DM patients requiring intensified glycemic
control
C. Patients with significant insulin resistance
D. Both B and C

7. Due to its mechanism of action, which of the following
should be stressed to the patient before taking dapagliflozin?
A. Increased foot care/monitoring
B. Increased HbA1c testing frequency
C. Adequate hydration
D. None of the above

2.

Which of the following is the mechanism of action associated with dapagliflozin therapy?
A. Agonist at SGLTl in the proximal convoluted
tubule
B. Agonist of intestinal SGLT2
C. Inhibitor of SGLT2 in the proximal convoluted
tubule
D. Inhibitor of intestinal SGL Tl

8. At what level of renal impairment should dapagliflozin
therapy be stopped?
A. Moderate to severe renal impairment
B. Moderate renal impairment only
C. Severe renal impairment only
D. Dapagliflozin should not be given with any renal
impairment

3.

What is the recommended starting dose when initiating
dapagliflozin?
A. 10 mg once daily
B. 100 mg twice weekly
C. 5 mg once daily
D. 5 mg BID

4.

Which dapagliflozin combination therapy resulted in
attenuated weight GAIN?
A. Dapagliflozin + metformin
B. Dapagliflozin + glimepiride
C. Dapagliflozin + pioglitazone

5.

Which dapagliflozin combination therapy resulted in
statistically significant differences from baseline HbA1c
compared to oral diabetic medication monotherapy plus
placebo?
A. Dapagliflozin + metformin
B. Dapagliflozin + glimepiride
C. Dapagliflozin + pioglitazone
D. All of the above

9.

6.

8

What side effect was noted with highest prevalence in
ALL the dapagliflozin combination therapies in the studies mentioned?
A. UTls
B. Genital infections
C. Hypoglycemia
D. All of the above

Dapagliflozin therapy in pregnant females is ...
A. Contraindicated
B. Not sufficiently studied, so risks should be evaluated prior to treatment
C. Indicated
D. Safe and effective

10. How did the incidence ofUTis compare between dapagliflozin and placebo treatments?
A. There was a higher incidence in all dapagliflozin
groups
B. There was a higher incidence in the 5 and 10 mg
dapagliflozin groups
C. There was a lower incidence in dapagliflozin
groups
D. There was a lower incidence in the 5 and 10 mg
dapagliflozin groups
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1

2

3

4

5

Identify the mechanism of action and pharmacological implications
of therapy with dapagliflozin.

1

2

3

4

5

Explain dapagliflozin's place in therapy in the treatment of diabetes.

1

2

3

4

5

Describe possible advantages of combination therapy with current
diabetes medications.

1

2

3

4

5

Identify the appropriate monitoring requirements for dapagliflozin
treatment.

1

2

3

4

5

The program met your educational needs.

1

2

3

4

5

Content of the program was interesting.

1

2

3

4

5

Material presented was relevant to my practice.

1

2

3

4

5

The program objectives were clear.
The program met the stated goals and objectives:

Discuss the various side effects associated with dapagliflozin use.

Comments/Suggestions for future programs:

Thank you!
Answers to Assessment Questions-Please Circle Your Answer
1.

A

B

2. A B
3. A B

c
c
c

D

4. A B

D

5.

D

6. A B

A B

c
c
c

7.
D

8. A B

D

9. A B

Any questions/comments regarding this continuing education program can
be directed to Lauren Hamman, Advanced Administrative Assistant for the
Office of Continuing Education (email: l-hamman@onu.edu, phone 419772-2280).

A B

c
c
c

~

D

10. A B

c

D

D
D
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